shutterstock_212432119

Opdivo + cabiralizumab combo falls flat in advanced pancreatic cancer

pharmafile | February 19, 2020 | News story | Research and Development |  Bristol-Myers Squibb, Five Prime Therapeutics, Pancreatic cancer, cabiralizumab, opdivo, pharma 

Five Prime Therapeutics and Bristol-Myers Squibb have confirmed that their randomised Phase 2 trial investigating the efficacy of the former’s cabiralizumab combined with the latter’s blockbuster immunotherapy Opdivo (nivolumab) in the treatment of advanced pancreatic cancer failed to meet its primary endpoint.

The combo fell short both with and without chemotherapy in a study of around 160 enrolled participants with locally advanced or metastatic or locally advanced or metastatic pancreatic cancer that had progressed despite having received one line of chemotherapy.  

“Pancreatic cancer is a difficult disease to treat, and unfortunately the combination of cabiralizumab and Opdivo with and without chemotherapy did not show any meaningful benefit over standard of care chemotherapy in this randomized, controlled Phase 2 trial,” said Dr Helen Collins, Executive Vice President and Chief Medical Officer of Five Prime Therapeutics. “We are disappointed by this outcome and appreciate the participation of the investigators, staff, patients, caregivers, and our development partner who all contributed to the conduct and completion of this Phase 2 clinical trial.”

Despite the failure, BMS confirmed that it would “continue to support” cabiralizumab in ongoing trials while weighing up future development opportunities, though it has no “near-term” plans for the drug.

Advertisement

Matt Fellows

Related Content

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Anocca secures £32m to advance pancreatic cancer trial

Swedish biopharma Anocca has raised approximately £32m (SEK 440m) to support the early-stage clinical development …

The Gateway to Local Adoption Series

Latest content